FRESENIUS KABI ONCOLOGY LTD
Fresenius Kabi Oncology Ltd, a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across various global regions. Founded in the early 2000s, the company has established itself as a leader in oncology, focusing on the development and manufacturing of high-quality injectable pharmaceuticals and infusion therapies. Specialising in oncology products, Fresenius Kabi Oncology is renowned for its commitment to patient safety and product efficacy. The company offers a diverse portfolio that includes chemotherapy agents and supportive care medications, distinguished by their rigorous quality standards and innovative delivery systems. With a strong market position, Fresenius Kabi Oncology has achieved significant milestones, including numerous regulatory approvals and partnerships that enhance its global reach. The company continues to advance cancer care, making a meaningful impact in the lives of patients worldwide.
DitchCarbon Score
How does FRESENIUS KABI ONCOLOGY LTD's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
FRESENIUS KABI ONCOLOGY LTD's score of 8 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
FRESENIUS KABI ONCOLOGY LTD's reported carbon emissions
In 2022, FRESENIUS KABI ONCOLOGY LTD reported total carbon emissions of approximately 1,321,000,000 kg CO2e, comprising about 563,000,000 kg CO2e from Scope 1 and about 758,000,000 kg CO2e from Scope 2 emissions. This marked a slight decrease in emissions compared to 2021, where total emissions were approximately 1,477,000,000 kg CO2e, with Scope 1 at about 578,000,000 kg CO2e and Scope 2 at about 899,000,000 kg CO2e. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The absence of documented reduction targets suggests that while FRESENIUS KABI ONCOLOGY LTD acknowledges the importance of climate action, it may not yet have formalised its strategies in line with industry standards such as the Science Based Targets initiative (SBTi). Overall, FRESENIUS KABI ONCOLOGY LTD's emissions data reflects a significant operational scale, and the company is positioned within a global context that increasingly prioritises sustainability and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
FRESENIUS KABI ONCOLOGY LTD is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
